Author

Happiness Mvungi

Observed names: Happiness C Mvungi, Happiness C. Mvungi, Happiness Cornel Mvungi, HappinessCornel Mvungi, Mvungi, Happiness Cornel

Institutions: Kilimanjaro Christian Medical Centre, KCMC University

Observed institutions: Kilimanjaro Christian Medical Centre, KCMC University, Kilimanjaro Clinical Research Institute, Government of Tanzania, Nelson Mandela African Institution of Science and Technology

ORCID: 0000-0001-6527-4887

Observed ORCID: 0000-0001-6527-4887

OpenAlex ID: A5113935019

Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania

2021 · Sagal Mohamed, Happiness C Mvungi, et al. · Journal of Antimicrobial Chemotherapy · 30

Blood cytokine responses to early secreted protein antigen-6/culture filtrate protein-10 tuberculosis antigens 2 months after antituberculosis treatment among patients with drug-susceptible pulmonary tuberculosis

2019 · HappinessCornel Mvungi, PeterMasunga Mbelele, et al. · International Journal of Mycobacteriology · 11

Patients’ acceptability, adherence and satisfaction on the modified shorter all-oral multidrug-resistant tuberculosis regimen: a two-phase cross-sectional study in Tanzania

2025 · Julieth Lalashowi, Happiness Mvungi, et al. · BMJ Open · 6

Clinical application of whole-genome sequencing in the management of extensively drug-resistant tuberculosis: a case report

2024 · Bugwesa Z. Katale, Sylvia Rofael, et al. · Annals of Clinical Microbiology and Antimicrobials · 5

N-Acetylcysteine to Reduce Kidney and Liver Injury Associated with Drug-Resistant Tuberculosis Treatment

2025 · Idu Meadows, Happiness Mvungi, et al. · Pharmaceutics · 3

Tuberculosis service delivery challenges and their mitigations during the COVID-19 pandemic in Tanzania: a qualitative study

2025 · Doreen Pamba, Erica Sanga, et al. · BMJ Open · 3

Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania

2023 · Stellah G. Mpagama, Happiness C. Mvungi, et al. · Pilot and Feasibility Studies · 3

Implementation of the ‘Removed Injectable modified Short-course regimens for EXpert Multidrug Resistant Tuberculosis’ (RISE study) in Tanzania: a protocol for a mixed-methods process evaluation

2022 · Albino Kalolo, Julieth Lalashowi, et al. · BMJ Open · 3

Comparative Treatment Outcomes of Shorter Regimen in Modified All Oral Regimen with Injectable in Patients Treated for Rifampicin-resistant/Multidrug-resistant Tuberculosis in Tanzania

2025 · Happiness Cornel Mvungi, Peter Masunga Mbelele, et al. · International Journal of Mycobacteriology

Prevalence and predictors of adverse events among patients receiving Multi-Drug Resistant Tuberculosis treatment at Kibong’oto Infectious Disease Hospital, Tanzania: a retrospective study

2023 · Abbas Said, Dennis Lyakurwa, et al. · Tanzania journal of health research/Tanzania Journal of Health Research

Analysis of plasma biomarkers and their association with treatment response in patients with tuberculosis

2019 · Mvungi, Happiness Cornel

Works count: 11

Citation count: 64

H-index: 4

I10-index: 2